• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad, July 8 Aiming to strengthen its global position, Veeda Oncology on Tuesday announced the acquisition of US-based International Oncology Network (ION) Clinical Research for an undisclosed financial consideration.

In addition, Veeda Oncology and ION agreed to a five-year exclusive agreement under which the former will provide clinical research support to the ION sites.

The acquisition of ION Clinical Research would provide Veeda with access to the 50 ION sites that conduct oncology clinical research in the US, a company statement said here. Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service oncology CRO for Phase I through Phase IV studies with the capability of providing global patient accrual with an effective cost structure.

Commenting on the acquisition, Mr Binoy Gardi, Co-Group Managing Director and Co-Founder, Veeda Group, said, “The agreement with ION increases our ability to provide our sponsors with global accrual of oncology patients beyond our relationships with institutions in India, Eastern and Western Europe as well as our current site relationships in the US.”

Mr Matt Bowman, President and Chief Executive Officer of Veeda Oncology, said, “The access to the 50 ION Clinical Research sites compliments our strategy of access to oncology patients for global clinical trials. In addition, all of the personnel of ION Clinical Research will be joining Veeda Oncology.”

More Stories on : Overseas Investments | Pharmaceuticals | Mergers & Acquisitions

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
SAT sets aside SEBI directive on Mysore Cements open offer

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line